Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Gastroenterol
    October 2020
  1. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    >> Share

  2. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    >> Share

    August 2020
  3. NAKAGAWA M, Nawa N, Takeichi E, Shimizu T, et al
    Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01715.
    >> Share

    February 2020
  4. TAKEHARA T, Chayama K, Kurosaki M, Yatsuhashi H, et al
    JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
    J Gastroenterol. 2020 Feb 17. pii: 10.1007/s00535-020-01672.
    >> Share

    November 2019
  5. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    >> Share

    September 2019
  6. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    >> Share

    June 2019
  7. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    >> Share

    March 2019
  8. SEZAKI H, Suzuki F, Hosaka T, Fujiyama S, et al
    Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    J Gastroenterol. 2019 Mar 22. pii: 10.1007/s00535-019-01575.
    >> Share

  9. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    >> Share

  10. TAKAGUCHI K, Toyoda H, Tsutsui A, Suzuki Y, et al
    Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2019 Mar 8. pii: 10.1007/s00535-019-01568.
    >> Share

    February 2019
  11. UEDA Y, Kobayashi T, Ikegami T, Miuma S, et al
    Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2019 Feb 26. pii: 10.1007/s00535-019-01561.
    >> Share

  12. SUDA G, Hasebe C, Abe M, Kurosaki M, et al
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. pii: 10.1007/s00535-019-01556.
    >> Share

    January 2019
  13. DOI A, Hikita H, Kai Y, Tahata Y, et al
    Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    J Gastroenterol. 2019 Jan 25. pii: 10.1007/s00535-018-01541.
    >> Share

  14. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.
    >> Share

    November 2018
  15. RAKSAYOT M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, et al
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    J Gastroenterol. 2018 Nov 30. pii: 10.1007/s00535-018-01533.
    >> Share

    October 2018
  16. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    >> Share

  17. OSAWA M, Imamura M, Teraoka Y, Uchida T, et al
    Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    J Gastroenterol. 2018 Oct 17. pii: 10.1007/s00535-018-1520.
    >> Share

    September 2018
  18. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    >> Share

    July 2018
  19. SUDA G, Kurosaki M, Itakura J, Izumi N, et al
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. pii: 10.1007/s00535-018-1495.
    >> Share

  20. MAEKAWA S, Enomoto N
    The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
    J Gastroenterol. 2018 Jul 6. pii: 10.1007/s00535-018-1493.
    >> Share

    May 2018
  21. TOYODA H, Atsukawa M, Takaguchi K, Senoh T, et al
    Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2018 May 8. pii: 10.1007/s00535-018-1473.
    >> Share

    April 2018
  22. TSUJI K, Kurosaki M, Itakura J, Mori N, et al
    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Gastroenterol. 2018 Apr 6. pii: 10.1007/s00535-018-1455.
    >> Share

    March 2018
  23. AKUTA N, Toyota J, Karino Y, Ikeda F, et al
    Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    J Gastroenterol. 2018 Mar 2. pii: 10.1007/s00535-018-1445.
    >> Share

    January 2018
  24. ZEUZEM S, Serfaty L, Vierling J, Cheng W, et al
    The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    J Gastroenterol. 2018 Jan 17. pii: 10.1007/s00535-018-1429.
    >> Share

  25. SUDA G, Ogawa K, Morikawa K, Sakamoto N, et al
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 Jan 3. pii: 10.1007/s00535-017-1427.
    >> Share

    November 2017
  26. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Nov 13. doi: 10.1007/s00535-017-1409.
    >> Share

  27. MAEKAWA S, Sato M, Kuratomi N, Inoue T, et al
    Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1405.
    >> Share

    October 2017
  28. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Oct 20. doi: 10.1007/s00535-017-1396.
    >> Share

  29. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    >> Share

    September 2017
  30. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    >> Share

    August 2017
  31. KAWAKAMI Y, Ochi H, Hayes CN, Imamura M, et al
    Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    J Gastroenterol. 2017 Aug 16. doi: 10.1007/s00535-017-1380.
    >> Share

    May 2017
  32. MIZUOCHI T, Takano T, Yanagi T, Ushijima K, et al
    Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.
    J Gastroenterol. 2017 May 31. doi: 10.1007/s00535-017-1351.
    >> Share

  33. SUDA G, Furusyo N, Toyoda H, Kawakami Y, et al
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2017 May 30. doi: 10.1007/s00535-017-1353.
    >> Share

    January 2017
  34. UEDA Y, Ikegami T, Akamatsu N, Soyama A, et al
    Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2017 Jan 30. doi: 10.1007/s00535-017-1310.
    >> Share

    December 2016
  35. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    >> Share

  36. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    >> Share

    November 2016
  37. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    >> Share

  38. MORIO K, Imamura M, Kawakami Y, Nakahara T, et al
    ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    J Gastroenterol. 2016.
    >> Share

    October 2016
  39. TAKEDA H, Takai A, Inuzuka T, Marusawa H, et al
    Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.
    J Gastroenterol. 2016.
    >> Share

    September 2016
  40. MORIO R, Imamura M, Kawakami Y, Morio K, et al
    Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    >> Share

    November 2015
  41. KAWAI-KITAHATA F, Asahina Y, Tanaka S, Kakinuma S, et al
    Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    J Gastroenterol. 2015.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016